URAC gives accreditation to PBM-owned specialty pharmacy
LISLE, Ill. — Washington-based accrediting organization URAC has accredited pharmacy benefit manager Catamaran Corp.’s specialty pharmacy brand, Catamaran said.
The PBM said BriovaRx had been awarded URAC’s Specialty Pharmacy Accreditation. Catamaran said URAC offered the only third-party, voluntary accreditation program of this scope for the pharmacy benefit management and prescription services industry.
"BriovaRx’s robust offerings focus on the patient, ensuring one-on-one support and a personalized plan that addresses chronic conditions to help them lead healthy, vibrant lives," Catamaran chairman and CEO Mark Thierer said. "The URAC accreditation is a reflection of BriovaRx’s patient-centric approach that coordinates the efforts of providers, payers and manufacturers to keep treatments personalized and successful."
URAC president and CEO Alan Spielman said BriovaRx’s application for and receiving of accreditation demonstrated "a commitment to quality health care."
No comments found
Dr. Reddy’s launches generic osteoporosis drug
HYDERABAD, India — Dr. Reddy’s Labs has launched zoledronic acid injection in the 5 mg-per-100-mL strength, the Indian generic drug maker Thursday.
The drug, launched following its approval by the Food and Drug Administration, is a generic version of Novartis’ Reclast and is used to treat osteoporosis. Reclast had sales of $355 million during the 12-month period that ended in February, according to IMS Health.
The launch follows last month’s launch of zoledronic acid injection in the 4-mg-per-5-mL, a generic version of Novartis’ Zometa, which is another version of the drug used to treat the cancer multiple myeloma and cancers that have spread to the bones.
CORRECTION: An earlier version of this story misstated the strength of Dr. Reddy’s generic version of Zometa. The story has been corrected.
Rite Aid front-end comps up 3.8% amid shift in timing of Easter
CAMP HILL, Pa. — Same-store sales at Rite Aid decreased 2% in March, including a 3.8% increase in same-store sales on the front end and a 4.5% decrease in pharmacy sales due in part to new introductions of generic drugs, the retail pharmacy chain said Thursday.
The 4,621-store chain reported total sales for the month of $1.939 billion, a 2.5% decrease compared with $1.989 billion in March 2012, while same-store prescription count increased 0.3%.
The company said that of the 3.8% increase in front-end same-store sales, 3% came from a shift in timing of Easter, which fell on March 31, as opposed to April 8 last year.
Investment firm Guggenheim Partners maintained its "Buy" rating on Rite Aid’s stock, saying it expected the company to post strong and above-trend growth in EBITDA in its fourth quarter 2012 earnings, which it will report next Thursday. Guggenheim analyst John Heinbockel noted that script count was below the 1.5% recent trendline, and the reason was unclear but appeared to be due to a weakening of the economy, but the firm expects the meaningful generic drug benefit to GM to persist into the first quarter of fiscal year 2014.
No comments found